EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans

Charlotte Laniece Delaunay, Clara Mazagatos, Iván Martínez-Baz, Gergo Túri, Luise Goerlitz, Lisa Domegan, Adam Meijer, Ana Paula Rodrigues, Noémie Sève, Maja Ilic, Neus Latorre-Margalef, Mihaela Lazar und 28 weitere

JAMA Network Open · 01.07.2024 · 7 (7) · e2419258

DOI: 10.1001/jamanetworkopen.2024.19258 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 01.07.2024. Verfasst von Charlotte Laniece Delaunay und 39 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology Department, Epiconcept, Paris, France. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Vaccine Efficacy, SARS-CoV-2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) to inform vaccination campaigns.

Objective

To estimate the effectiveness of COVID-19 vaccines administered in autumn and winter 2022 to 2023 against symptomatic SARS-CoV-2 infection (with all circulating viruses and XBB lineage in particular) among people aged 60 years or older in Europe, and to compare different CVE approaches across the exposed and reference groups used. Design, Setting, and Participants This case-control study obtained data from VEBIS (Vaccine Effectiveness, Burden and Impact Studies), a multicenter study that collects COVID-19 and influenza data from 11 European sites: Croatia; France; Germany; Hungary; Ireland; Portugal; the Netherlands; Romania; Spain, national; Spain, Navarre region; and Sweden. Participants were primary care patients aged 60 years or older with acute respiratory infection symptoms who were recruited at the 11 sites after the start of the COVID-19 vaccination campaign from September 2022 to August 2023. Cases and controls were defined as patients with positive and negative, respectively, reverse transcription–polymerase chain reaction (RT-PCR) test results. Exposures The exposure was COVID-19 vaccination. The exposure group consisted of patients who received a COVID-19 vaccine during the autumn and winter 2022 to 2023 vaccination campaign and 14 days or more before symptom onset. Reference group included patients who were not vaccinated during or in the 6 months before the 2022 to 2023 campaign (seasonal CVE), those who were never vaccinated (absolute CVE), and those who were vaccinated with at least the primary series 6 months or more before the campaign (relative CVE). For relative CVE of second boosters, patients receiving their second booster during the campaign were compared with those receiving 1 booster 6 months or more before the campaign. Main Outcomes and Measures The outcome was RT-PCR–confirmed, medically attended, symptomatic SARS-CoV-2 infection. Four CVE estimates were generated: seasonal, absolute, relative, and relative of second boosters. CVE was estimated using logistic regression, adjusting for study site, symptom onset date, age, chronic condition, and sex.

Results

A total of 9308 primary care patients were included, with 1687 cases (1035 females; median [IQR] age, 71 [65-79] years) and 7621 controls (4619 females [61%]; median [IQR] age, 71 [65-78] years). Within 14 to 89 days after vaccination, seasonal CVE was 29% (95% CI, 14%-42%), absolute CVE was 39% (95% CI, 6%-60%), relative CVE was 31% (95% CI, 15% to 44%), and relative CVE of second boosters was 34% (95% CI, 18%-47%) against all SARS-CoV-2 variants. In the same interval, seasonal CVE was 44% (95% CI, −10% to 75%), absolute CVE was 52% (95% CI, −23% to 82%), relative CVE was 47% (95% CI, −8% to 77%), and relative CVE of second boosters was 46% (95% CI, −13% to 77%) during a period of high XBB circulation. Estimates decreased with time since vaccination, with no protection from 180 days after vaccination. Conclusions and Relevance In this case-control study among older Europeans, all CVE approaches suggested that COVID-19 vaccines administered in autumn and winter 2022 to 2023 offered at least 3 months of protection against symptomatic, medically attended, laboratory-confirmed SARS-CoV-2 infection. The effectiveness of new COVID-19 vaccines against emerging SARS-CoV-2 variants should be continually monitored using CVE seasonal approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesVaccine EfficacySARS-CoV-2SeasonsHumansAgedFemaleEuropeMaleMiddle AgedCase-Control StudiesAged, 80 and overVaccinationEuropean People

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Epidemiology Department, Epiconcept, Paris, France.
  • National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Instituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain.
  • National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
  • Department for Infectious Disease Epidemiology, Unit 36 Respiratory Infections, Robert Koch Institute, Berlin, Germany.

Zitieren

APA

Laniece Delaunay, C., Mazagatos, C., Martínez-Baz, I., Túri, G., Goerlitz, L., Domegan, L., Meijer, A., Rodrigues, A. P., Sève, N., Ilic, M., Latorre-Margalef, N., Lazar, M., Maurel, M., Melo, A., Andreu Ivorra, B., Casado, I., Horváth, J. K., Buda, S., Bennett, C., …, & VEBIS Primary Care Vaccine Effectiveness Group (2024). COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans. JAMA Network Open, 7(7), e2419258. https://doi.org/10.1001/jamanetworkopen.2024.19258

Vancouver

Laniece Delaunay C, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, et al. COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans. JAMA Network Open. 2024;7(7):e2419258. doi:10.1001/jamanetworkopen.2024.19258

BibTeX
@article{LanieceDelaunay2024,
  author = {Laniece Delaunay, Charlotte and Mazagatos, Clara and Martínez-Baz, Iván and Túri, Gergo and Goerlitz, Luise and Domegan, Lisa and Meijer, Adam and Rodrigues, Ana Paula and Sève, Noémie and Ilic, Maja and Latorre-Margalef, Neus and Lazar, Mihaela and Maurel, Marine and Melo, Aryse and Andreu Ivorra, Blanca and Casado, Itziar and Horváth, Judit Krisztina and Buda, Silke and Bennett, Charlene and de Lange, Marit and Guiomar, Raquel and Enouf, Vincent and Mlinaric, Ivan and Samuelsson Hagey, Tove and Dinu, Sorin and Rumayor, Mercedes and Castilla, Jesús and Oroszi, Beatrix and Dürrwald, Ralf and O'Donnell, Joan and Hooiveld, Mariëtte and Gomez, Verónica and Falchi, Alessandra and Kurecic Filipovic, Sanja and Dillner, Lena and Popescu, Rodica and Bacci, Sabrina and Kaczmarek, Marlena and Kissling, Esther and VEBIS Primary Care Vaccine Effectiveness Group, VEBIS Primary Care Vaccine Effectiveness Group},
  title = {COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {7},
  pages = {e2419258},
  doi = {10.1001/jamanetworkopen.2024.19258}
}
Kostenlos starten →